journal article·2026-07-01Open access

Osmotic Remodeling of Extracellular Vesicles for Precision Nanomedicine

Francesca Susa, Lorenzo Arnaboldi, Veronica De Giorgis, Marco Ghirimoldi, Elettra Barberis, Marco Brucale, Francesco Valle, Mario Malerba, Marta Vallino, Angelo Musicò, Roberto Frigerio, Alessandro Gori, Vera Mugoni, Claudia Voena, Roberto Pisano, Fabrizio Pirri, Silvia Arpicco, Marcello Manfredi, Tania Limongi

Abstract

ABSTRACT Extracellular vesicles (EVs) are increasingly explored as diagnostic and therapeutic platforms. Translation is constrained by protocols that must balance efficacy and safety, especially for EVs from tumor or immortalized cells that may carry oncogenic or immunostimulatory cargo. This study presents a rapid and reproducible engineering of EVs using bidistilled water as the sole reagent. The hypotonic environment induces osmotic lysis of EVs isolated from B lymphocytes, generating a remodeled vesicle population. The process markedly reduces a broad spectrum of intraluminal components with potential immunogenic or tumor‐promoting activity, while preserving the vesicular membrane scaffold. Osmotic remodeling is associated with reorganization of membrane‐associated lipids and proteins and with a preferential uptake of the remodeled vesicles by tumor cells over non‐malignant counterparts in our in vitro model. The engineered EVs retain structural integrity and are amenable, at a proof‐of‐concept level, to reloading with defined bioactive compounds, suggesting their potential as customizable delivery systems. Overall, this osmotic remodeling strategy provides a versatile technological platform for the generation of membrane‐derived vesicles with tunable properties and promising applicability in drug delivery, nanodiagnostics, and immune modulation, whose translational performance and safety will need to be established in source‐ and indication‐specific preclinical studies.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Drug Science and Technology University of Torino Torino Italy

Department of Pharmacological and Biomolecular Sciences “Rodolfo Paoletti” Università degli Studi di Milano Milano Italy

Department of Translational Medicine Center For Allergic and Autoimmune Diseases University of Piemonte Orientale Novara Italy

Department of Sciences and Technological Innovation Center For Allergic and Autoimmune Diseases University of Piemonte Orientale Alessandria Italy

Consiglio Nazionale delle Ricerche—Istituto per lo Studio dei Materiali Nanostrutturati (CNR‐ISMN) Bologna Italy

Istituto Nazionale di Ricerca Metrologica (INRIM) Torino Italy

Consiglio Nazionale delle Ricerche (CNR) di Torino Torino Italy

Istituto Di Scienze e Tecnologie Chimiche “Giulio Natta” National Research Council of Italy (SCITEC‐CNR) Milano Italy

Department of Molecular Biotechnology and Health Sciences Molecular Biotechnology Center University of Torino Torino Italy

Department of Applied Science and Technology Politecnico Di Torino Torino Italy

Institute for Molecular and Translational Cardiology (IMTC) IRCCS Policlinico San Donato Milano Italy

References (100+)

Show source-provided references
1. 10.1002/jev2.1214410.1002/jev2.12144 ↗
2. 10.1038/s41392‐024‐01735‐110.1038/s41392‐024‐01735‐1 ↗
3. 10.1038/s41565‐024‐01774‐310.1038/s41565‐024‐01774‐3 ↗
4. 10.3390/biology1309071610.3390/biology13090716 ↗
5. Fan X. · 2024
6. 10.1002/jev2.1233210.1002/jev2.12332 ↗
7. 10.3390/ijms2512653310.3390/ijms25126533 ↗
8. 10.1016/j.reth.2025.02.00810.1016/j.reth.2025.02.008 ↗
9. 10.1186/s13046‐025‐03403‐w10.1186/s13046‐025‐03403‐w ↗
10. 10.1038/s41392‐025‐02262‐310.1038/s41392‐025‐02262‐3 ↗
11. 10.1186/s40580‐024‐00426‐510.1186/s40580‐024‐00426‐5 ↗
12. 10.3389/fbioe.2023.130787810.3389/fbioe.2023.1307878 ↗
13. 10.1186/s13578‐022‐00784‐910.1186/s13578‐022‐00784‐9 ↗
14. 10.1242/jcs.25916610.1242/jcs.259166 ↗
15. 10.1186/s12943‐025‐02282‐110.1186/s12943‐025‐02282‐1 ↗
16. 10.1038/s41577‐022‐00763‐810.1038/s41577‐022‐00763‐8 ↗
17. 10.1038/s41565‐021‐00931‐210.1038/s41565‐021‐00931‐2 ↗
18. 10.1038/s42003‐023‐04911‐110.1038/s42003‐023‐04911‐1 ↗
19. 10.1186/s43556‐024‐00230‐x10.1186/s43556‐024‐00230‐x ↗
20. 10.1038/s41573‐022‐00410‐w10.1038/s41573‐022‐00410‐w ↗
21. 10.1155/2021/661124410.1155/2021/6611244 ↗
22. 10.4103/1673‐5374.26690810.4103/1673‐5374.266908 ↗
23. 10.1186/s12907‐015‐0005‐510.1186/s12907‐015‐0005‐5 ↗
24. 10.1016/j.semcancer.2021.05.01110.1016/j.semcancer.2021.05.011 ↗
25. 10.1186/s12987‐022‐00359‐310.1186/s12987‐022‐00359‐3 ↗
26. 10.3390/cells1407054810.3390/cells14070548 ↗
27. 10.3390/pharmaceutics1607084910.3390/pharmaceutics16070849 ↗
28. 10.3389/fcell.2021.73472010.3389/fcell.2021.734720 ↗
29. 10.1016/j.ajps.2022.10.00210.1016/j.ajps.2022.10.002 ↗
30. 10.3390/ijms2403234410.3390/ijms24032344 ↗
31. 10.1016/j.cophys.2025.10081510.1016/j.cophys.2025.100815 ↗
32. 10.1016/j.vesic.2024.10005810.1016/j.vesic.2024.100058 ↗
33. 10.1161/CIRCRESAHA.123.32305410.1161/CIRCRESAHA.123.323054 ↗
34. 10.1038/jcbfm.2013.15210.1038/jcbfm.2013.152 ↗
35. 10.3390/ijms22231286010.3390/ijms222312860 ↗
36. 10.1161/JAHA.121.02433010.1161/JAHA.121.024330 ↗
37. 10.2147/ijn.S37285110.2147/ijn.S372851 ↗
38. 10.3389/fimmu.2023.128493610.3389/fimmu.2023.1284936 ↗
39. 10.3390/bioengineering910049610.3390/bioengineering9100496 ↗
40. 10.1016/j.bioactmat.2022.02.01310.1016/j.bioactmat.2022.02.013 ↗
41. 10.1038/ncomms118010.1038/ncomms1180 ↗
42. 10.1002/jev2.1219810.1002/jev2.12198 ↗
43. 10.1002/elps.20200022310.1002/elps.202000223 ↗
44. 10.1016/j.ymthe.2023.02.01310.1016/j.ymthe.2023.02.013 ↗
45. 10.1016/j.addr.2021.03.02010.1016/j.addr.2021.03.020 ↗
46. 10.1021/acsabm.1c0080410.1021/acsabm.1c00804 ↗
47. 10.1016/j.bioactmat.2022.07.02210.1016/j.bioactmat.2022.07.022 ↗
48. 10.1039/D3NA00280B10.1039/D3NA00280B ↗
49. 10.1016/j.ijpharm.2019.11880210.1016/j.ijpharm.2019.118802 ↗
50. 10.1021/acsabm.4c0065810.1021/acsabm.4c00658 ↗
51. 10.1016/j.reth.2024.07.00610.1016/j.reth.2024.07.006 ↗
52. Piffoux M. · 2022
53. 10.3389/fphar.2022.83979010.3389/fphar.2022.839790 ↗
54. 10.1002/advs.20230055210.1002/advs.202300552 ↗
55. 10.1002/bit.2819810.1002/bit.28198 ↗
56. 10.1038/s41598‐019‐44487‐710.1038/s41598‐019‐44487‐7 ↗
57. 10.1080/71384032910.1080/713840329 ↗
58. Review on Resealed Erythrocytes as a Novel Drug Delivery System
59. 10.1016/j.heliyon.2023.e2345110.1016/j.heliyon.2023.e23451 ↗
60. 10.1021/acs.jctc.3c0096110.1021/acs.jctc.3c00961 ↗
61. 10.1016/j.bpj.2017.03.01810.1016/j.bpj.2017.03.018 ↗
62. 10.1021/acs.langmuir.8b0302610.1021/acs.langmuir.8b03026 ↗
63. 10.1038/s41598‐017‐02599‐y10.1038/s41598‐017‐02599‐y ↗
64. 10.1016/S0001‐8686(00)00067‐110.1016/S0001‐8686(00)00067‐1 ↗
65. 10.1017/S003358350000164510.1017/S0033583500001645 ↗
66. Lipowsky R. · 1995
67. 10.1103/PhysRevE.64.04191310.1103/PhysRevE.64.041913 ↗
68. 10.1002/jex2.5710.1002/jex2.57 ↗
69. 10.1038/ncomms802910.1038/ncomms8029 ↗
70. 10.1002/bies.20120004510.1002/bies.201200045 ↗
71. 10.1016/j.colsurfb.2022.11272810.1016/j.colsurfb.2022.112728 ↗
72. 10.1002/jev2.1248110.1002/jev2.12481 ↗
73. 10.1083/jcb.20121113810.1083/jcb.201211138 ↗
74. 10.1021/acs.analchem.9b0571610.1021/acs.analchem.9b05716 ↗
75. 10.1002/jev2.1234910.1002/jev2.12349 ↗
76. 10.1002/med.2186810.1002/med.21868 ↗
77. 10.3389/fmolb.2024.144364210.3389/fmolb.2024.1443642 ↗
78. 10.3389/fcell.2021.67391710.3389/fcell.2021.673917 ↗
79. 10.1007/s13238‐017‐0423‐510.1007/s13238‐017‐0423‐5 ↗
80. 10.3389/fmolb.2023.119804410.3389/fmolb.2023.1198044 ↗
81. 10.1016/j.plipres.2020.10106810.1016/j.plipres.2020.101068 ↗
82. 10.1016/j.plipres.2017.03.00110.1016/j.plipres.2017.03.001 ↗
83. 10.1101/cshperspect.a04141510.1101/cshperspect.a041415 ↗
84. 10.1016/j.atherosclerosis.2024.11856910.1016/j.atherosclerosis.2024.118569 ↗
85. 10.1002/jev2.1226010.1002/jev2.12260 ↗
86. 10.1002/jev2.7004910.1002/jev2.70049 ↗
87. 10.2183/pjab.85.1210.2183/pjab.85.12 ↗
88. 10.1016/s0092‐8674(03)00971‐110.1016/s0092‐8674(03)00971‐1 ↗
89. 10.1038/nri362210.1038/nri3622 ↗
90. 10.3402/jev.v4.2706610.3402/jev.v4.27066 ↗
91. 10.1038/nprot.2008.21110.1038/nprot.2008.211 ↗
92. 10.1146/annurev‐cellbio‐101512‐12232610.1146/annurev‐cellbio‐101512‐122326 ↗
93. 10.1039/D4NH00320A10.1039/D4NH00320A ↗
94. 10.1021/acs.jpcc.1c0891410.1021/acs.jpcc.1c08914 ↗
95. 10.1016/j.colsurfb.2024.11436610.1016/j.colsurfb.2024.114366 ↗
96. 10.1039/D5NH00292C10.1039/D5NH00292C ↗
97. 10.1038/s41467‐024‐52205‐910.1038/s41467‐024‐52205‐9 ↗
98. 10.1021/acsnano.2c0775110.1021/acsnano.2c07751 ↗
99. 10.3389/fbioe.2019.0045210.3389/fbioe.2019.00452 ↗
100. 10.1096/fj.08‐12341410.1096/fj.08‐123414 ↗